.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,951,969

« Back to Dashboard

Claims for Patent: 8,951,969

Title:Compositions and methods for treating centrally mediated nausea and vomiting
Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
Inventor(s): Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee: Helsinn Healthcare SA (Lugano/Pazzallo, CH)
Application Number:14/069,885
Patent Claims: 1. An oral pharmaceutical dosage form comprising about 0.56 mg of palonosetron hydrochloride and about 300 mg of netupitant as the free base.

2. An oral pharmaceutical dosage form in the form of a capsule comprising a hard outer shell, three tablets comprising about 100 mg of netupitant each, and one soft-gel capsule comprising about 0.56 mg of palonosetron hydrochloride, wherein the tablets and soft-gel capsule are housed within the hard outer shell.

3. The oral dosage form of claim 2, comprising 0.56 mg of palonosetron hydrochloride and 300 mg of netupitant as the free base.

4. The oral dosage form of claim 2, further comprising (3S)-3-[(3aS)-1-oxo-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinoline-2-yl]- -1-azoniabicyclo[2.2.2]octan-1-olate in an amount that does not exceed 3 wt. %.

5. The oral dosage form of claim 2, wherein said outer shell of said capsule has an oxygen permeability of less than 1.0.times.10.sup.-3 mlcm/(cm.sup.224 hr. atm).

6. The oral dosage form of claim 2, wherein each of said soft-gel capsules comprises an inner fill composition comprising from about 75 to about 98 wt. % of one or more lipophilic components.

7. A dosage form formulated for oral administration comprising a therapeutically effective amount of a) netupitant and b) palonosetron, wherein a single dose of the composition provides a median t.sub.max of netupitant that is about 0.5 hours shorter than is provided by a single dose of a composition having the same amount of netupitant alone.

8. A pharmaceutical composition formulated for oral administration comprising a therapeutically effective amount of a) netupitant and b) palonosetron, wherein a single dose of the composition provides a greater area under the curve (AUC) of netupitant than is provided by a single dose of a composition having the same amount of netupitant alone.

9. The pharmaceutical composition of claim 8, wherein the composition further provides a greater C.sub.max of netupitant than is provided by a single dose of a composition having the same amount of netupitant alone.

10. The pharmaceutical composition of claim 8, wherein the composition further provides a shorter t.sub.max of netupitant than is provided by a single dose of a composition having the same amount of netupitant alone.

11. The pharmaceutical composition of claim 10, wherein the median t.sub.max of netupitant is 0.5 hour shorter than is provided by a single dose of a composition having the same amount of netupitant alone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc